The cure rate of early-stage liver cancer is relatively high, and most patients can achieve a better prognosis through treatment mainly based on surgical resection, and some patients can achieve clinical cure, with a 5-year survival rate of up to 80%. Early-stage liver cancer (also known as small liver cancer) generally refers to liver cancer in which the maximum diameter of a single cancerous nodule does not exceed 3 centimeters, or the number of multiple cancerous nodules does not exceed two, and the sum of their maximum diameters is less than 3 centimeters. Currently, there are many treatments for early-stage liver cancer, including surgical resection, (radiofrequency or microwave) ablation, TACE (percutaneous selective hepatic artery cannulation and perfusion chemotherapy and embolization), radiotherapy, and bio-immunotherapy. As early liver cancer patients have better liver reserve function, surgical resection is recommended as the first choice of treatment for early liver cancer, which can achieve lower local recurrence rate and better long-term therapeutic effect. However, clinically, liver cancer has an insidious onset and lacks typical symptoms in early stage, and most of the patients with obvious clinical symptoms have already entered the middle or late stage. For patients diagnosed with early-stage liver cancer, it is recommended to seek timely medical treatment, early intervention by doctors under the guidance of doctors, regular rechecking of liver cancer markers (alpha-fetoprotein, etc.) and imaging tests (ultrasound, CT and magnetic resonance imaging, i.e., MRI, etc.), and maintaining optimism, and there is a possibility of cure.